Update on Functional Inhibitors of Acid Sphingomyelinase (FIASMAs) in SARS-CoV-2 Infection

The SARS-CoV-2 outbreak is characterized by the need of the search for curative drugs for treatment. In this paper, we present an update of knowledge about the interest of the functional inhibitors of acid sphingomyelinase (FIASMAs) in SARS-CoV-2 infection. Forty-nine FIASMAs have been suggested in...

Descripción completa

Detalles Bibliográficos
Autores principales: Loas, Gwenolé, Le Corre, Pascal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Perspective
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8308787/
https://www.ncbi.nlm.nih.gov/pubmed/34358117
http://dx.doi.org/10.3390/ph14070691
_version_ 1783728364777897984
author Loas, Gwenolé
Le Corre, Pascal
author_facet Loas, Gwenolé
Le Corre, Pascal
author_sort Loas, Gwenolé
collection PubMed
description The SARS-CoV-2 outbreak is characterized by the need of the search for curative drugs for treatment. In this paper, we present an update of knowledge about the interest of the functional inhibitors of acid sphingomyelinase (FIASMAs) in SARS-CoV-2 infection. Forty-nine FIASMAs have been suggested in the treatment of SARS-CoV-2 infection using in silico, in vitro or in vivo studies. Further studies using large-sized, randomized and double-blinded controlled clinical trials are needed to evaluate FIASMAs in SARS-CoV-2 infection as off-label therapy.
format Online
Article
Text
id pubmed-8308787
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-83087872021-07-25 Update on Functional Inhibitors of Acid Sphingomyelinase (FIASMAs) in SARS-CoV-2 Infection Loas, Gwenolé Le Corre, Pascal Pharmaceuticals (Basel) Perspective The SARS-CoV-2 outbreak is characterized by the need of the search for curative drugs for treatment. In this paper, we present an update of knowledge about the interest of the functional inhibitors of acid sphingomyelinase (FIASMAs) in SARS-CoV-2 infection. Forty-nine FIASMAs have been suggested in the treatment of SARS-CoV-2 infection using in silico, in vitro or in vivo studies. Further studies using large-sized, randomized and double-blinded controlled clinical trials are needed to evaluate FIASMAs in SARS-CoV-2 infection as off-label therapy. MDPI 2021-07-18 /pmc/articles/PMC8308787/ /pubmed/34358117 http://dx.doi.org/10.3390/ph14070691 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Perspective
Loas, Gwenolé
Le Corre, Pascal
Update on Functional Inhibitors of Acid Sphingomyelinase (FIASMAs) in SARS-CoV-2 Infection
title Update on Functional Inhibitors of Acid Sphingomyelinase (FIASMAs) in SARS-CoV-2 Infection
title_full Update on Functional Inhibitors of Acid Sphingomyelinase (FIASMAs) in SARS-CoV-2 Infection
title_fullStr Update on Functional Inhibitors of Acid Sphingomyelinase (FIASMAs) in SARS-CoV-2 Infection
title_full_unstemmed Update on Functional Inhibitors of Acid Sphingomyelinase (FIASMAs) in SARS-CoV-2 Infection
title_short Update on Functional Inhibitors of Acid Sphingomyelinase (FIASMAs) in SARS-CoV-2 Infection
title_sort update on functional inhibitors of acid sphingomyelinase (fiasmas) in sars-cov-2 infection
topic Perspective
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8308787/
https://www.ncbi.nlm.nih.gov/pubmed/34358117
http://dx.doi.org/10.3390/ph14070691
work_keys_str_mv AT loasgwenole updateonfunctionalinhibitorsofacidsphingomyelinasefiasmasinsarscov2infection
AT lecorrepascal updateonfunctionalinhibitorsofacidsphingomyelinasefiasmasinsarscov2infection

Ejemplares similares